TABLE 2.
Summary of preclinical studies with FAK inhibitors.
| Inhibitor | Molecular targets | Cancer types | PMID |
|---|---|---|---|
| BI-853520 (IN10018) | FAK | Prostate cancer; breast cancer | 29472531; 30237500 |
| GSK2256098 | FAK | Pancreatic cancer; ovarian cancer | 25486573; 27064283 |
| NVP-TAC544 | FAK | N/A | 18391070 |
| PF-431396 | FAK/PYK2 | Pancreatic cancer | 19244237 |
| PF-573228 | FAK | Pleural mesothelioma; lung cancer | 29303405; 17395594 |
| TAE226 | FAK/IGF-IR | Breast cancer; ovarian carcinoma; hepatocellular carcinoma | 17849451; 17431114; 34784956 |
| VS-4718 | FAK/PYK2 | Breast cancer/ovarian cancer; pancreatic cancers | 27376576; 20234191 |
| VS-6062 | FAK/PYK2 | Gliomas; pancreatic cancer; colon cancer; lung cancer; prostate cancer; breast cancer | 18339875; 18339875; 22454420 |
| VS-6063 | FAK/PYK2 | Ovarian cancer; Hepatocellular carcinoma | 24062525; 35154476 |
| C4 | FAK-VEGFR3 interaction | Breast cancer | 19610651 |
| R2 | FAK-p53 interaction | Colorectal cancer | 23841915 |
| Y11 | FAK | Colon cancer and breast cancer | 22402131 |
| Y15 | FAK | Breast cancer; lung cancer | 18989950; 27336608 |